Q4 2024 Inovio Pharmaceuticals Inc Earnings Call Transcript

Mar 18, 2025 / 08:30 PM GMT

Release Date Price: MXN40

Transcript 8-K10-K

Key Points

Positve

Inovio Pharmaceuticals Inc (INO) has resolved the manufacturing issue with the single-use array component of the Selectra device, which is crucial for their BLA submission for INO 3,107.
The company plans to begin the BLA submission process in mid-2025, with the goal of FDA acceptance by the end of the year.
Clinical data for INO 3,107 shows significant and durable clinical benefits, with a reduction in the need for surgeries for RRP patients.
Inovio Pharmaceuticals Inc (INO) has made progress in developing their DNA encoded monoclonal antibody technology, showing durable in vivo production in humans.
The company has reduced operational expenses by 22% from 2023 to 2024, demonstrating effective cost management.

Negative

Inovio Pharmaceuticals Inc (INO) experienced delays in resolving the manufacturing issue, which took longer than initially expected.
The company reported a net loss of $107.3 million for the full year of 2024, indicating ongoing financial challenges.
Cash and cash equivalents decreased significantly from $145.3 million in 2023 to $94.1 million in 2024, raising concerns about financial sustainability.
The company needs to initiate a confirmatory trial before the BLA submission, which could pose additional challenges and delays.
There is uncertainty regarding the long-term epidemiology and market size for RRP, as vaccination rates and disease prevalence could impact future demand.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

INO.OQ - Inovio Pharmaceuticals Inc
Q4 2024 Inovio Pharmaceuticals Inc Earnings Call
Mar 18, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon ladies and gentlemen, and welcome to the Inovio Pharmaceuticals 4th quarter 2024 financial results conference call. At this time, all lines are in lesson only mode. Following the presentation, we will conduct a question and answer session. If at any time during this call you require immediate assistance, please press 0 for the operator. This call is being recorded on Tuesday, March 18, 2025, and I would not like to turn a conference over to Ms. Jenny Wilson.

Thank you. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Good

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.